Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, MontrealCanadian ophthalmic device company presents interventional glaucoma portfolio, launches digital presence, and invites surgeons to a hands-on OBi™ Core and OBi™ Gon dry lab at the COS Annual Meeting in Montreal
Hexiris Welcomes Paul Sowyrda and Steven Schiffman to Its Board of DirectorsDIEPPE, New Brunswick, March 04, 2025 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a leading R&D medtech company dedicated to developing innovative, accessible, and effective ophthalmic solutions for patients and community ophthalmologists, is pleased to announce the appointment of Paul Sowyrda and Steven Schiffman to its Board of Directors.
Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific CommitteeDIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee. Dr. Ahmed is globally renowned for his skills and groundbreaking work in the diagnosis and surgical treatment of highly complex eye diseases including glaucoma and surgical complications. Part of his numerous achievements include pioneering work in innovative glaucoma surgery, developing and coining the term ‘MIGS’ as a new genre of surgical approaches and devices.
